Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OPGNNASDAQ:PIIINASDAQ:QIPTNASDAQ:RNLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOPGNOpGen$4.70-3.7%$4.26$0.53▼$5.25$47.32M-1.7110,352 shs6,618 shsPIIIP3 Health Partners$7.30-4.1%$8.64$7.00▼$33.73$52.43M0.9420,407 shs6,679 shsQIPTQuipt Home Medical$1.81+3.1%$2.07$1.35▼$4.07$77.78M0.65354,614 shs760,733 shsRNLXRenalytix$0.21$0.23$0.18▼$2.40$17.18M2.721.45 million shs934,496 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOPGNOpGen-3.69%-4.08%-4.08%+282.11%+37.03%PIIIP3 Health Partners-4.07%-8.64%-17.89%-29.88%-70.92%QIPTQuipt Home Medical+3.14%+28.01%-15.26%-28.94%-43.77%RNLXRenalytix0.00%0.00%0.00%0.00%-52.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/APIIIP3 Health Partners2.4051 of 5 stars3.35.00.00.01.80.80.6QIPTQuipt Home Medical1.6934 of 5 stars3.51.00.00.01.71.70.6RNLXRenalytixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOPGNOpGen 0.00N/AN/AN/APIIIP3 Health Partners 2.50Moderate Buy$16.25122.60% UpsideQIPTQuipt Home Medical 3.00Buy$2.8557.89% UpsideRNLXRenalytix 3.00Buy$3.001,348.58% UpsideCurrent Analyst Ratings BreakdownLatest RNLX, QIPT, PIII, and OPGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025QIPTQuipt Home MedicalBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $4.005/13/2025QIPTQuipt Home MedicalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$4.00 ➝ $1.704/21/2025PIIIP3 Health PartnersLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $20.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOPGNOpGen$2.67M17.70N/AN/A($11.55) per share-0.41PIIIP3 Health Partners$1.49B0.04$3.15 per share2.32$0.45 per share16.22QIPTQuipt Home Medical$240.85M0.32$0.71 per share2.56$2.47 per share0.73RNLXRenalytix$2.29M7.50N/AN/A($0.10) per share-2.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%6/2/2025 (Estimated)PIIIP3 Health Partners-$57.77M-$47.28N/AN/AN/A-6.95%-71.31%-11.93%8/6/2025 (Estimated)QIPTQuipt Home Medical-$6.76M-$0.21N/AN/AN/A-2.90%-6.70%-2.94%N/ARNLXRenalytix-$33.46M-$0.39N/A∞N/A-1,461.60%N/A-281.40%N/ALatest RNLX, QIPT, PIII, and OPGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PIIIP3 Health Partners-$5.00-$6.28-$1.28-$6.28$362.09 million$373.23 million5/12/2025Q2 2025QIPTQuipt Home Medical$0.02-$0.07-$0.09-$0.07$88.29 million$57.40 million3/27/2025Q4 2024PIIIP3 Health Partners-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOPGNOpGenN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/AQIPTQuipt Home MedicalN/AN/AN/AN/AN/ARNLXRenalytixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOPGNOpGenN/A5.455.45PIIIP3 Health Partners1.110.530.53QIPTQuipt Home Medical0.741.220.87RNLXRenalytixN/A0.530.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOPGNOpGen2.68%PIIIP3 Health Partners7.75%QIPTQuipt Home Medical42.85%RNLXRenalytix9.92%Insider OwnershipCompanyInsider OwnershipOPGNOpGen43.80%PIIIP3 Health Partners17.79%QIPTQuipt Home Medical13.40%RNLXRenalytix18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOPGNOpGen10010.07 million4.70 millionNot OptionablePIIIP3 Health Partners5007.18 million294.74 millionNot OptionableQIPTQuipt Home Medical80043.09 million37.32 millionOptionableRNLXRenalytix10082.96 million63.06 millionOptionableRNLX, QIPT, PIII, and OPGN HeadlinesRecent News About These CompaniesRenalytix shares gain as billable test numbers set new company recordApril 10, 2025 | proactiveinvestors.co.ukRenalytix Adjusts Share Capital Amid Fundraising ShortfallNovember 6, 2024 | markets.businessinsider.comRenalytix PLC (RNLX) Stock: Unveiling Its Hidden StrengthsOctober 2, 2024 | bovnews.comRenalytix PLC (RNLX) Stock: Surpassing Expectations in the Market?September 11, 2024 | bovnews.comWhat Factors Have Led to Renalytix PLC (RNLX) Stock Trading -90.00% Below Its 52-Week High?September 2, 2024 | bovnews.comThe Renalytix Plc ADR (RNLX) Stock expansion path aheadJuly 23, 2024 | bovnews.comRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond USJuly 11, 2024 | globenewswire.comRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting DeterminationJune 27, 2024 | globenewswire.comMedicare Issues Final Coverage Determination for kidneyintelX.dkdJune 14, 2024 | globenewswire.comWhat do you think? Take A Moment To Read: Renalytix Plc ADR (RNLX) StockMay 27, 2024 | bovnews.comIs Renalytix Plc ADR (RNLX) Stock Paving the Way for Earnings?May 16, 2024 | bovnews.comRNLX Stock Earnings: Renalytix Misses EPS, Misses Revenue for Q3 2024May 15, 2024 | investorplace.comRenalytix AI GAAP EPS of -$0.08 beats by $0.01, revenue of $0.54M misses by $0.56MMay 15, 2024 | msn.comRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2024May 15, 2024 | globenewswire.comRenalytix AI is about to announce its earnings — here's what Wall Street expectsMay 15, 2024 | markets.businessinsider.comRenalytix AI earnings: here's what Wall Street expectsMay 14, 2024 | markets.businessinsider.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15May 9, 2024 | finance.yahoo.comRenalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15May 9, 2024 | globenewswire.comRenalytix Plc (RNLX) Stock Price, News, Quote & History - Yahoo FinanceApril 28, 2024 | finance.yahoo.comRenalytix files to sell 19.99M ordinary shares for holdersApril 17, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNLX, QIPT, PIII, and OPGN Company DescriptionsOpGen NASDAQ:OPGN$4.70 -0.18 (-3.69%) As of 05/23/2025 03:43 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.P3 Health Partners NASDAQ:PIII$7.30 -0.31 (-4.07%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.28 -0.02 (-0.34%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.Quipt Home Medical NASDAQ:QIPT$1.80 +0.06 (+3.14%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.84 +0.04 (+1.94%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.Renalytix NASDAQ:RNLXRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
